Clinical efficacy of CDK4/6 inhibitor rechallenge after progression on prior CDK4/6 inhibitor treatment in HR+/HER2− metastatic breast cancer (MBC): a systematic review and meta-analysis

First Author / 第一作者

Shu-Han Chang

Institution / 單位

Department of Oncology, National Taiwan University Hospital

Audio / 音訊檔

Author Group / 作者群

Zola Chia-Chen Li1 , Wen-Yi Shau2 , Yen-Shen Lu1

Author Group Institution/ 作者群單位

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan1. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan2

Category / 主題分類

Clinical Research

Keyword / 關鍵字

1. HR+/ HER2- MBC, 2. CDK4/6 inhibitor 3. Rechallenge

Back to list